Introduction: The Drugs & Cosmetics Act and Schedule Y form the backbone of clinical trial regulation and safety reporting in India. For B. Pharm students, understanding these laws is essential: they define “new drug,” outline protocol submission, investigator responsibilities, ethics committee review, and post‑marketing surveillance. Schedule Y specifically frames clinical trial phases, essential documents, bioavailability/bioequivalence requirements, and pharmacovigilance obligations such as Serious Adverse Event (SAE) identification and reporting. Key regulatory bodies include CDSCO and the DCGI, while Good Clinical Practice and compensation rules protect participant welfare. This concise knowledge prepares you for regulatory compliance and patient safety responsibilities. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. Which legislation governs the manufacture, sale and import of drugs in India?
- The Drugs & Cosmetics Act, 1940
- The Food Safety and Standards Act, 2006
- The Clinical Establishments Act, 2010
- The Pharmacy Act, 1948
Correct Answer: The Drugs & Cosmetics Act, 1940
Q2. Schedule Y is a part of which rules related to drug regulation?
- Pharmacy Practice Rules
- Drugs and Cosmetics Rules, 1945
- National Medical Commission Regulations
- Income Tax Rules
Correct Answer: Drugs and Cosmetics Rules, 1945
Q3. What is the primary purpose of Schedule Y?
- To regulate hospital licensing
- To provide guidelines for clinical trials and new drug approval
- To manage drug pricing
- To standardize pharmaceutical education
Correct Answer: To provide guidelines for clinical trials and new drug approval
Q4. What does DCGI stand for?
- Drug Council of General India
- Drug Controller General of India
- Directorate of Clinical Governance India
- Department of Chemicals and General Inspection
Correct Answer: Drug Controller General of India
Q5. Which organization is the central regulatory authority for drugs in India?
- WHO India
- Central Drugs Standard Control Organization (CDSCO)
- Indian Pharmacopoeia Commission
- National Institute of Virology
Correct Answer: Central Drugs Standard Control Organization (CDSCO)
Q6. Which of the following events qualifies as a Serious Adverse Event (SAE)?
- Mild transient headache lasting one hour
- Temporary injection site redness
- Hospitalization or its prolongation
- Minor laboratory value fluctuation within reference range
Correct Answer: Hospitalization or its prolongation
Q7. Who is primarily responsible for initial reporting of an SAE occurring at a trial site?
- Sponsor only
- Investigator to sponsor and ethics committee
- Regulatory authority directly
- Pharmacovigilance centre only
Correct Answer: Investigator to sponsor and ethics committee
Q8. Which party is responsible for aggregate safety reporting and notifying the regulatory authority about unexpected SAEs?
- Investigator
- Sponsor
- Study volunteer
- Ethics committee secretary
Correct Answer: Sponsor
Q9. The Investigator’s Brochure primarily contains which type of information?
- Marketing strategy for the investigational product
- Preclinical, pharmacology and available clinical data on the investigational product
- Investigator personal financial disclosures
- Generic drug pricing details
Correct Answer: Preclinical, pharmacology and available clinical data on the investigational product
Q10. What is the minimum characteristic of an ethics committee as required for clinical trial review?
- Composed only of clinicians from the same specialty
- Multidisciplinary with at least one lay person
- Must be chaired by the sponsor
- Comprised exclusively of institutional administrators
Correct Answer: Multidisciplinary with at least one lay person
Q11. Which elements are essential components of informed consent?
- Voluntariness, adequate information, comprehension and documentation
- Only voluntary signature without information
- Sponsor approval stamp only
- Investigator verbal consent without record
Correct Answer: Voluntariness, adequate information, comprehension and documentation
Q12. GCP in clinical research stands for:
- General Clinical Procedures
- Good Clinical Practice
- Global Consent Protocol
- Guidelines for Clinical Pharmacology
Correct Answer: Good Clinical Practice
Q13. The primary objective of a Phase I clinical trial is to:
- Demonstrate long‑term efficacy in thousands of patients
- Assess safety, tolerability and pharmacokinetics in healthy volunteers or patients
- Obtain marketing approval
- Perform large post‑marketing surveillance
Correct Answer: Assess safety, tolerability and pharmacokinetics in healthy volunteers or patients
Q14. Phase III trials are primarily designed to:
- Explore mechanism of action in animals
- Compare efficacy and safety in larger patient populations to support regulatory approval
- Test formulation stability only
- Study pharmacokinetics in healthy volunteers
Correct Answer: Compare efficacy and safety in larger patient populations to support regulatory approval
Q15. Bioavailability and bioequivalence studies are specifically important for:
- Novel surgical devices only
- Comparing systemic exposure of different formulations or generic vs reference drugs
- Measuring marketing effectiveness
- Assessing hospital infection rates
Correct Answer: Comparing systemic exposure of different formulations or generic vs reference drugs
Q16. What is the role of a Contract Research Organization (CRO) in clinical trials?
- Grant regulatory permissions on behalf of the government
- Conduct one or more trial‑related duties on behalf of the sponsor
- Provide healthcare to trial subjects independent of the protocol
- Act as the ethics committee
Correct Answer: Conduct one or more trial‑related duties on behalf of the sponsor
Q17. According to Schedule Y, what must a sponsor submit to obtain permission for a clinical trial?
- Clinical trial protocol and supporting preclinical/clinical data
- Only the investigator’s CV
- Marketing brochures
- Patient lists from previous trials
Correct Answer: Clinical trial protocol and supporting preclinical/clinical data
Q18. How does an SAE differ from a non‑serious adverse event?
- SAE is expected and non‑serious is always unexpected
- SAE results in outcomes like death, hospitalization or disability; non‑serious events do not
- Non‑serious events always require regulatory notification
- There is no practical difference
Correct Answer: SAE results in outcomes like death, hospitalization or disability; non‑serious events do not
Q19. Which authority grants permission to conduct clinical trials in India?
- Local municipal corporation
- Drug Controller General of India (DCGI) through CDSCO
- State weather department
- University academic council
Correct Answer: Drug Controller General of India (DCGI) through CDSCO
Q20. Which of the following is an essential trial document per Schedule Y?
- Case Report Form (CRF)
- Product marketing leaflet for final sold product only
- Investigator’s private appointments book
- Company payroll records
Correct Answer: Case Report Form (CRF)
Q21. SUSAR in clinical pharmacovigilance means:
- Standard Unrelated Safety Adverse Report
- Suspected Unexpected Serious Adverse Reaction
- Scheduled Universal Safety Audit Record
- Systematic Unverified Safety Alert Report
Correct Answer: Suspected Unexpected Serious Adverse Reaction
Q22. What should follow an initial SAE report from an investigator?
- No further action required
- Detailed follow‑up report providing outcome and investigator assessment
- Immediate trial publication in a journal
- Destruction of all trial records
Correct Answer: Detailed follow‑up report providing outcome and investigator assessment
Q23. Which body issues compensation guidelines and oversight for clinical trial injuries in India?
- World Bank
- Central Drugs Standard Control Organization (CDSCO)
- Local police
- Reserve Bank of India
Correct Answer: Central Drugs Standard Control Organization (CDSCO)
Q24. What is the investigator’s main duty regarding the investigational product at site?
- Maintain accountability records and ensure proper storage and dispensing
- Market the product locally
- Provide the product free to non‑trial patients indefinitely
- Modify the product formulation without sponsor consent
Correct Answer: Maintain accountability records and ensure proper storage and dispensing
Q25. Which document typically contains the statistical analysis plan for a clinical trial?
- Investigator’s brochure
- Clinical trial protocol (or an attached SAP)
- Informed consent form
- Ethics committee meeting minutes
Correct Answer: Clinical trial protocol (or an attached SAP)
Q26. Which phase of clinical development focuses on post‑marketing surveillance?
- Phase I
- Phase II
- Phase III
- Phase IV
Correct Answer: Phase IV
Q27. Registration of ethics committees for clinical trials in India is required with which authority?
- Local chamber of commerce
- Central Drugs Standard Control Organization (CDSCO)
- State education board
- National Stock Exchange
Correct Answer: Central Drugs Standard Control Organization (CDSCO)
Q28. A critical aim of SAE reporting under Schedule Y and regulatory practice is to:
- Increase product sales
- Ensure participant safety and enable regulatory oversight for risk mitigation
- Replace informed consent
- Delay trial completion indefinitely
Correct Answer: Ensure participant safety and enable regulatory oversight for risk mitigation
Q29. Which of the following is included in a complete SAE report?
- Patient identifier, event description, onset date, outcome and investigator assessment
- A single word “serious” without details
- Only the sponsor’s opinion without clinical data
- Marketing claims about the drug
Correct Answer: Patient identifier, event description, onset date, outcome and investigator assessment
Q30. ICH, an international body relevant to harmonizing clinical trial standards, stands for:
- International Committee for Health
- Indian Council for Health
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
- Institute for Clinical Hospitals
Correct Answer: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
